Are Skyrocketing Drug Prices Really Needed for Innovation?

Are Skyrocketing Drug Prices Really Needed for Innovation?   Amgen’s earnings report today indicates that R&D costs fell 14% while drug prices continue to climb.  Enbrel’s price […]

Read more

ICYMI: National Journal article features CSRxP’s White Paper

This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.”

Read more

New Drug Report Confirms Drug Prices On Unsustainable Path

Reaction from National Coalition on Health Care President and CEO John Rother on key findings from the “Express Scripts 2014 Drug Trend Report.”

Read more

Speaking Engagements Broaden Discussion on Unsustainable Drug Prices

John Rother to Make Appearances at AMA National Advocacy Conference and National Conference of Insurance Legislators. 

Read more